The companies aim to provide an end-to-end solution for acquiring, reading and reporting the results of MRI brain scans. They hope to optimize the diagnosis and treatment monitoring of neurological conditions, including Alzheimer’s and multiple sclerosis (MS).
According to a news release, the offering integrates Icometrix’s AI-powered quantitative reporting software into Philips’ latest BlueSeal MR scanners. The Dutch medtech giant just debuted new BlueSeal technology last week. Additionally, they plan to deploy software on Philips’ healthcare informatics platform, including its cloud-based AI Manager.
Philips and Icometrix unveiled their solution at RSNA 2024.
The companies say that advanced MRI can help identify the most suitable candidates for new drugs slowing the progression of Alzheimer’s. AI can extract quantitative measurements from brain scans, enhancing the diagnostic process and enabling quicker decision-making.
Icometrix’s IcoBrain DM software offers differential dementia diagnosis, while its FDA-cleared ARIA software provides computer-aided detection and diagnosis for the grade and severity of amyloid-related imaging abnormalities.
“Philips is at the forefront of applying AI to help save time and improve diagnostic accuracy so clinicians can deliver better care to more patients,” said Shez Partovi, chief innovation & strategy officer at Philips. “As these innovations continue to evolve, they hold great promise for transforming the landscape of neurological care, offering hope for better management of chronic conditions like Alzheimer’s and MS.
“Our partnership with Icometrix is an important step forward in the use of AI to help mitigate staff shortages, lower the cost of care, increase diagnostic confidence, and facilitate care orchestration of personalized plans for the growing number of people who are diagnosed with Alzheimer’s disease.”
